TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers studying human brain tissue and mice linked lower NRF2 levels in oligodendrocytes—the cells that maintain myelin—to abnormal myelin, loss of large nerve fibers and faster cognitive decline. The findings identify a possible treatment pathway, but do not show that NRF2-targeting drugs prevent age-related decline in people.
A study published in Nature Medicine links lower levels of the protective protein NRF2 in oligodendrocytes—brain cells that maintain nerve insulation—to abnormal myelin, loss of large nerve fibers and faster cognitive decline. The researchers examined people in a long-running aging cohort and conducted experiments in mice; the results point to a possible treatment pathway, but do not establish that a drug can prevent cognitive decline in people.
The research, led by scientists from the University of Edinburgh and the UK Dementia Research Institute, drew on the Lothian Birth Cohort 1936. Participants’ cognitive abilities had been tracked from childhood. Between ages 70 and 82, researchers assessed memory, processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional cognitive testing after age 70, with the pace of change differing among participants.
In post-mortem brain tissue from a subset of the cohort, people who had experienced greater decline tended to have fewer large nerve fibers and an abnormal accumulation of myelin, the fatty coating that helps electrical signals travel along nerve fibers. The reported tissue changes were associated with the rate of cognitive decline, rather than a person’s test performance at one particular age.
The team then investigated oligodendrocytes, which produce and maintain myelin. In people with more pronounced decline, researchers found lower NRF2 levels in these cells. NRF2 regulates genes involved in cellular defenses and normal function. In mice, reducing NRF2 specifically in oligodendrocytes led to excess myelin, fewer large nerve fibers and less improvement on cognitive tests as the animals aged. The experiments support a role for NRF2 in the observed changes, but animal results do not demonstrate a treatment effect in humans.
A New Target in Brain Aging
The findings suggest that age-related cognitive change may involve not only damage to nerve fibers, but also problems in the cells responsible for maintaining their insulation. Oligodendrocytes are generally understood as supportive cells; the study indicates that when their function changes, they may contribute to abnormalities that affect communication in the brain.
The work also identifies NRF2 activity as a potential research target. The source report notes that medicines acting on this pathway are already used for other neurological conditions, including multiple sclerosis. That makes the pathway relevant to future research, but it does not mean those medicines are established or proven treatments for cognitive decline associated with aging.
For readers, the distinction is important: the research offers a biological explanation worth testing, not a current clinical option. Any possible benefit, suitable treatment, dose and risks for older adults would need to be studied directly.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The Lothian Birth Cohort provides an unusual opportunity to compare brain tissue with cognitive measurements collected across many years. In this study, that history let researchers examine whether differences in the pace of decline corresponded with structural changes found in tissue after participants died. The tissue analysis was limited to a subset of the cohort, so it cannot by itself establish that the observed changes caused each person’s cognitive decline.
The researchers used mouse experiments to test whether changing NRF2 in oligodendrocytes could produce related effects. The reported similarities between the human tissue findings and the mouse results strengthen the case for further investigation. Still, a mouse model cannot reproduce the full complexity of human aging, and the study does not show that the pathway accounts for all cognitive decline.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
oligodendrocyte support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Treatment Benefits Remain Unproven
The study does not establish whether reduced NRF2 activity starts the process in people, results from other age-related changes, or acts alongside other causes. The human findings are observational, while the experiments that reduced NRF2 were conducted in mice. The source report does not specify the size of the human tissue subset or provide enough detail to judge how broadly the results apply across different populations.
It is also unknown whether medicines that affect NRF2 could safely restore oligodendrocyte function in older adults, or whether doing so would slow cognitive decline. Prior findings involving NRF2-targeting drugs in people with multiple sclerosis concern a different condition and do not answer that question. No clinical trial showing prevention or treatment of age-related decline is described in the report.
As an affiliate, we earn on qualifying purchases.
Testing the Pathway in People
The next step is to establish how NRF2 activity and oligodendrocyte changes relate to cognitive trajectories in further studies, and whether modifying the pathway can protect nerve fibers without harmful effects. Researchers would then need clinical trials in older adults to test whether a specific medicine changes cognitive outcomes, as well as to assess safety and identify who might benefit.
Until those studies are done, the reported work is best understood as evidence of a possible mechanism and a therapeutic research lead. It does not support using an existing neurological drug to treat or prevent ordinary age-related cognitive decline.
cognitive health supplements for seniors
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are oligodendrocytes?
Oligodendrocytes are brain cells that produce and maintain myelin, the insulating material around nerve fibers. Myelin helps electrical signals move along those fibers.
What did the study find in human brain tissue?
In a subset of participants, greater cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. The tissue findings show an association, not proof that these changes caused decline.
Did the researchers prove that NRF2-targeting drugs prevent cognitive decline?
No. The study identified a possible pathway and tested changes in mice. It did not report a clinical trial showing that NRF2-targeting medicines prevent or treat age-related cognitive decline in people.
Why does the research mention multiple sclerosis drugs?
The source report says the NRF2 pathway is targeted by medicines used for other neurological conditions, including multiple sclerosis. Their existing use makes the pathway of interest for further study, but does not establish that those medicines work for age-related cognitive decline.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
